Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Tax Provisions (2020 - 2025)

Tango Therapeutics has reported Tax Provisions over the past 6 years, most recently at -$55000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at -$55000.0 for Q4 2025, down 212.24% from a year ago — trailing twelve months through Dec 2025 was $4000.0 (down 98.08% YoY), and the annual figure for FY2025 was $4000.0, down 98.08%.
  • Tax Provisions for Q4 2025 was -$55000.0 at Tango Therapeutics, down from -$10000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for TNGX hit a ceiling of $185000.0 in Q4 2021 and a floor of -$55000.0 in Q4 2025.
  • Median Tax Provisions over the past 5 years was $40000.0 (2024), compared with a mean of $42529.4.
  • Biggest five-year swings in Tax Provisions: surged 3233.33% in 2023 and later tumbled 212.24% in 2025.
  • Tango Therapeutics' Tax Provisions stood at $185000.0 in 2021, then plummeted by 72.43% to $51000.0 in 2022, then tumbled by 33.33% to $34000.0 in 2023, then soared by 44.12% to $49000.0 in 2024, then tumbled by 212.24% to -$55000.0 in 2025.
  • The last three reported values for Tax Provisions were -$55000.0 (Q4 2025), -$10000.0 (Q3 2025), and $35000.0 (Q2 2025) per Business Quant data.